TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06389487

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine
Description: 1 dose of RSVPreF3 OA investigational vaccine is administered intramuscularly on Day 1;

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine
Description: 1 dose of RSVPreF3 OA investigational vaccine is administered intramuscularly on Day 1;

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine
Description: 1 dose of RSVPreF3 OA investigational vaccine is administered intramuscularly on Day 1;
Study: NCT06514378

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: Endobronchial administration of 10⁶ MSCs/kg in each transplanted lung, 4 weeks apart.
Study: NCT05939115

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark)
Description: TMS Therapy System with Theta Burst Stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark)
Description: TMS Therapy System with Theta Burst Stimulation
Study: NCT05021289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: guided imagery
Description: guided imagery
Study: NCT06501495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video polysomnography
Description: video polysomnography during 2 nights

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attention task
Description: Attention task : SART Test (Sustained Attention to Response Task)
Study: NCT04970472

Intervention type: BIOLOGICAL
Intervention: collection of blood, urines, stool and tumor samples
Description: blood, urines, stool will be collected during routine cares. Tumor samples from surgery will also be stored.
Study: NCT04984317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxin A
Description: One-time injection of 100U BOTOX
Study: NCT06648460

Intervention type: OTHER
Group type: OTHER
Intervention: Effort-based Decision-Making Task
Description: Virtual Reality-based multi-stage task in which individuals must explore distinct rooms in a virtual environment that vary in the amount of effort (walking) and reward (points) they receive.
Study: NCT06595459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Pouches
Description: 3mg or 6mg nicotine pouches

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Pouches
Description: 3mg or 6mg nicotine pouches

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mini Nicotine lozenges
Description: 2mg to 4mg mini lozenges
Study: NCT05749068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CapScan intestinal sampling device
Description: CapScan is an intestinal collection device used to characterize the regional distribution of sulfasalazine, the metabolic breakdown products of sulfasalazine, and the gut microbiota in the digestive tracts of healthy volunteers.
Study: NCT06619938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness With Biofeedback
Description: The intervention includes two weekly 90-minute sessions of brief mindfulness training, covering mindfulness practices, psychoeducation on caregiving, and group sharing. After the first session, participants receive a wearable device for biofeedback on RR, HR, HRV, EDA, and sleep patterns to support mindfulness practice and reduce stress. A 30-minute session teaches caregivers how to use the devices and understand the parameters. The study uses Fitbit Sense with Fitbit apps, employing PPG sensors. The Fitbit Sense connects to smartphones with the apps installed. Caregivers can: (1) view real-time RR, HR, HRV, and EDA on the device and trends on their phone; (2) receive mindfulness practice reminders; (3) access audio coaching; (4) set personal goals (e.g., 30 minutes of daily practice); (5) track practice duration; (6) rate daily stress; and (7) review sleep quality. After the second session, caregivers practice mindfulness for 30 minutes daily over eight weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Without Biofeedback
Description: The control group will receive two weekly sessions of brief mindfulness training, the same as the intervention group. After the 1st brief mindfulness training, the control group will receive a 30-minute briefing session on goal setting for mindfulness practice. Each caregiver will be asked to develop an action plan for continuous mindfulness practice. A mindfulness therapist will also discuss the challenges and solutions for developing a habit of mindfulness practice with the caregivers in the second session. Caregivers in the control group will be advised to practice mindfulness daily for 30 minutes over the course of eight weeks.
Study: NCT06621667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diaphragmatic myofascial release with traditional physical therapy exercises for hyperkyphosis
Description: diaphragmatic myofascial release

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy exercises for hyperkyphosis
Description: traditional physical therapy exercises for hyperkyphosis
Study: NCT06623669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MORPH
Description: A remote behavioral intervention combining coaching and digital health tools to improve diet and activity behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Measurement Only
Description: This intervention entails receipt of a body weight scale and wearable activity monitor.
Study: NCT06620341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: drug education
Description: * Training: Train emergency doctors every month on how to use antibiotic infusion reasonably; The prescription, cancellation, or method of use of antibiotics is decided by doctors.~  * Implementation of intervention cards: When the C-reactive protein (CRP) of patients is exceed 10mg/L, the doctor should determine whether to use antibiotics based on the clinical status of patients.~    * Promotion: Promote reasonably use of intravenous antibiotics through public accounts and posters.~      * Patient education: Distribute educational flyers to patients about how to use antibiotics reasonably.
Study: NCT06623305

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: Light therapy will be administered using the cluster probe on the external cheeks bilaterally and intraorally using the lollipop probe for patients ≥7 years of age. Patients \&lt; 7 years of age will not receive intraoral treatment with the lollipop. Instead, they will be asked to open their mouth while the covered cluster probe is held externally to treat their intraoral membranes. Each treatment (both external cheeks and intraoral buccal region) will be administered over 1 min with a Modulation Frequency 2.5Hz, Skin Conduction nS 001, and Beam Power mW 000, for a total treatment time of 3 minutes.
Study: NCT06623279

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HG202
Description: Method of Administration: Once unilateral subretinal injection; The duration of the study includes a 4-week screening period, enrollment visit, treatment visit and 52 weeks follow-up period, 4 more years long term follow up as an extension study.
Study: NCT06621056

Intervention type: OTHER
Intervention: not applicable for observational research
Description: This is an observational research and has no intervention

Intervention type: OTHER
Intervention: not applicable for observational research
Description: This is an observational research and has no intervention
Study: NCT06730620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test preparation：Methylcholine chloroacetate for inhalation
Description: Cholinergic agonists

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference preparation：Methylcholine chloroacetate for inhalation（(Provocholin）
Description: Cholinergic agonists
Study: NCT06730906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PACTAID App
Description: The PACTAID app will provide real time decision support during exercise for patients with type 1 diabetes.
Study: NCT06730477

Intervention type: OTHER
Intervention: observational study
Description: Efficacy of targeted therapy combined with or without chemotherapy as first-line therapy in patients with EGFR-mutated lung adenocarcinoma.

Intervention type: OTHER
Intervention: observational study
Description: Efficacy of targeted therapy combined with or without chemotherapy as first-line therapy in patients with EGFR-mutated lung adenocarcinoma.

Intervention type: OTHER
Intervention: observational study
Description: Efficacy of targeted therapy combined with or without chemotherapy as first-line therapy in patients with EGFR-mutated lung adenocarcinoma.
Study: NCT05107466

Intervention type: DIAGNOSTIC_TEST
Intervention: P300 Visually evoked potential
Description: Measurement of the late cortical response, P300 potential to visually evoked stimuli using an oddball paradigm.

Intervention type: DIAGNOSTIC_TEST
Intervention: P300 Visually evoked potential
Description: Measurement of the late cortical response, P300 potential to visually evoked stimuli using an oddball paradigm.
Study: NCT05366413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Referral
Description: Directing a patient for a pain specialist consult earlier than standardly occurs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Management Strategies
Description: Specialized plan with procedures to ease pain
Study: NCT05723926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vine Filter
Description: The Vine filters are designed to be implanted in the common carotid arteries in order to capture emboli coming from the heart or great vessels, before they can enter the anterior intracranial circulation. The filter is deployed percutaneously using a 22G needle under ultrasound guidance.
Study: NCT05675800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin administered with psychological support

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin administered with psychological support
Study: NCT04980404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inqovi
Description: Tablet combination of drugs decitabine and cedazuridine, given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inqovi
Description: Tablet combination of drugs decitabine and cedazuridine, given orally.
Study: NCT05673161

Intervention type: OTHER
Intervention: iron
Description: iron treatment
Study: NCT05976308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bushen Huatan Decoction
Description: The treatment group used Bushen Huatan Decoction, including Tusizi (the seed of Chinese dodder), Fupenzi (Raspberry), Bajitian (Morinda officinalis), Duzhong (Eucommia ulmoides), Shudi (prepared Rehmanniaroot), Fuling (Tuckahoe), Zelan (Aconitum gymnandrum), Zexie (Rhizoma alismatis), Guizhi (Cassia twig), Zhebeimu (Thunberg Fritillary Bulb), Taoren (Peach kernel) and Chuanxiong (Ligusticum wallichii). Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment group used Caramel pigment, Ku Ding Cha Extracts, Maltodextrin, Starch and 5% Bushen Huatan Decoction.
Study: NCT05724459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer education
Description: Training on stem cell transplantation for a total of 12 hours, two days a week for three weeks, two lesson hours a day (60 min. + 60 min.)
Study: NCT06245447

Intervention type: OTHER
Intervention: Retrospective evaluation of specific brain MRI features
Description: * Brain MRI changes in the acute stage, i.e. \< 3 months from symptoms onset, including abnormal signal intensity, altered diffusion and/or contrast enhancement in the hippocampus (unilateral/bilateral), abnormal signal intensity in basal ganglia, insula, and/or perisylvian cortex, presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry~* Brain MRI changes after acute phase resolution (\> 6 months after symptoms onset) including abnormal signal intensity in the hippocampus (unilateral/bilateral), presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry

Intervention type: OTHER
Intervention: Retrospective evaluation of specific brain MRI features
Description: * Brain MRI changes in the acute stage, i.e. \< 3 months from symptoms onset, including abnormal signal intensity, altered diffusion and/or contrast enhancement in the hippocampus (unilateral/bilateral), abnormal signal intensity in basal ganglia, insula, and/or perisylvian cortex, presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry~* Brain MRI changes after acute phase resolution (\> 6 months after symptoms onset) including abnormal signal intensity in the hippocampus (unilateral/bilateral), presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry
Study: NCT06521580

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Description: Open reduction and internal fixation of those with osteopetrosis and weight bearing fractures
Study: NCT05188547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video education
Description: Participants will be shown a video educating them on anesthesia and perioperative instructions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video education
Description: Participants will be shown a video educating them on anesthesia and perioperative instructions.
Study: NCT06190184

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VIOME Precision Nutrition Program
Description: Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control arm
Description: Participants who have mental health issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and/or supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.
Study: NCT06136507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FRSW107
Description: experimental：Q3D.≥50EDs， Expansion phase：Q3D.100EDs
Study: NCT05428241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Behavioral: 6 sessions of Motivational Interviewing and 3-month follow-up. 6 sessions of Motivational Interview will be applied to the working group. All sessions will be in the form of face-to-face meetings. Each interview will take an average of 45-60 minutes. With this intervention, it was aimed to increase the levels of coping with motivational interviewing, functionality, adherence to treatment and quality of life in bipolar disorder patients. Study data consists of personal information form, Morisky Treatment Adherence Scale (MMAS), World Health Organization Quality of Life Scale, Short Form (WHOQOL-BREF), Assessment of Coping Attitudes Inventory (COPE), Bipolar Disorder Functioning Questionnaire (BDFQ). Data will be analyzed pre-intervention, post-intervention and 3 months post-intervention. A drug and device will not be administered to participants.
Study: NCT04902196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity cardiorespiratory exercise protocol
Description: During the high intensive cardiorespiratory exercise protocol, a bicycle ergometer (eBike Basic, General Electric GmbH, Bitz, Germany) with pulmonary gas exchange analysis (MetaMax 3B, Cortex Biophysik GmbH, Leipzig, Germany) will be used. Oxygen uptake (VO2max), expiratory volume (VE) and respiratory exchange rate (RER) will be tracked every breath and an average will be taken every 10s. Heart rate is continuously monitored using a heart rate chest strap (Polar Electro Inc., Finland). After a five-minute warm-up, a high-intensity interval protocol is started, consisting of five one-minute bouts (110 reps/minute at 100% VO2max workload), separated by one minute of active rest (75 reps per minute at 50% VO2max workload).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high intensity cardiorespiratory exercise protocol
Description: During the high intensive cardiorespiratory exercise protocol, a bicycle ergometer (eBike Basic, General Electric GmbH, Bitz, Germany) with pulmonary gas exchange analysis (MetaMax 3B, Cortex Biophysik GmbH, Leipzig, Germany) will be used. Oxygen uptake (VO2max), expiratory volume (VE) and respiratory exchange rate (RER) will be tracked every breath and an average will be taken every 10s. Heart rate is continuously monitored using a heart rate chest strap (Polar Electro Inc., Finland). After a five-minute warm-up, a high-intensity interval protocol is started, consisting of five one-minute bouts (110 reps/minute at 100% VO2max workload), separated by one minute of active rest (75 reps per minute at 50% VO2max workload).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate intensity cardiorespiratory exercise protocol
Description: During the moderate intensive cardiorespiratory exercise protocol, a bicycle ergometer (eBike Basic, General Electric GmbH, Bitz, Germany) with pulmonary gas exchange analysis (MetaMax 3B, Cortex Biophysik GmbH, Leipzig, Germany) will be used. Oxygen uptake (VO2max), expiratory volume (VE) and respiratory exchange rate (RER) will be tracked every breath and an average will be taken every 10s. Heart rate is continuously monitored using a heart rate chest strap (Polar Electro Inc., Finland). After a five-minute warm-up, participants begin a moderately-intensive continuous 14-minute exercise protocol at a stable resistance (90 repetitions per minute at 60% VO2max workload).
Study: NCT06390007

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham press needle
Description: The plester used is a round plaster that resembles the shape of an acupuncture press needle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Press needle acupuncture
Description: Press needle acupuncture is a modality of acupuncture using tiny and very thin needles.
Study: NCT05959811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga
Description: 60 minutes yoga practice ,twice a week for 8 weeks
Study: NCT04193709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Epidural Stimulation
Description: For arm 2, optimal stimulation parameters (cathode/anode configuration, stimulation frequency and voltage; placement of electrode from L1 to S1) will be identified for blood pressure and bladder pressure to achieve a bladder capacity in the target normative range of 400-450 mLs. Spinal cord epidural stimulation will then be used in a controlled lab setting for the regulation of blood pressure and heart rate to maintain normative values (target systolic pressure of 110-120 mmHg) and bladder pressure below 10 cmH2O during bladder filling up to the targeted capacity (fill volume of 400 mLs).
Study: NCT03559868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Participants will receive 3 mcg/Kg/day doses of oral digoxin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Participants will receive 0.15 mcg/Kg/day doses of oral digoxin
Study: NCT05473741

Intervention type: DRUG
Intervention: Second Generation Long-Acting Injectable Antipsychotic Medications
Description: Patients who have been stabilized on long-acting injectable formulations of paliperidone palmitate, risperidone and aripiprazole will be followed for 48 weeks to determine the rate of relapse when adherence is established. Blood samples to measure plasma antipsychotic levels and prolactin levels, and urine samples for drug screen will be collected at baseline and at the 24-week and 48-week time points.
Study: NCT04765995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZBio1 0.96mg / kg
Description: HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZBio1 3mg / kg
Description: HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZBio1 6mg / kg
Description: HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZBio1 9mg / kg
Description: HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZBio1 12mg / kg
Description: HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered intramuscularly.
Study: NCT05735990

Intervention type: DEVICE
Intervention: Intraocular lens
Description: Aspheric hydrophilic acrylic IOL for implantation into the capsular bag
Study: NCT05295979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inflammatory skin disease formula
Description: ISDF granules (10.85g twice daily) for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo granules (10.85g twice daily) for 12 weeks
Study: NCT06119334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online intervention
Description: Phone counselling for 1 hour/week over 16 weeks and access to the online platform with health promotion materials (videos, text, audios)
Study: NCT06100692

Intervention type: DRUG
Intervention: Vitamin D
Description: the patients will receive a 30 pts a combination of oral vit D and zinc